



New Clinical Trial Opportunity

- **Dementia with Lewy Bodies**
- **Parkinson's Disease Dementia**

SiteRx is excited to announce the launch of a new clinical research study in partnership with Eisai Inc. Now available to all network providers



**Immediate
Patient Need**

200

E2027 is actively recruiting nationally for DLB and PDD populations

Clinical Trial Summary

- E2027 is a phase 2, open-label 9-month trial
- Treatment includes oral dosing for 12 weeks
- Complementary testing includes MRI, DaT scan, various labs and lumbar puncture

Key Inclusion Criteria

- Stable symptomatic treatment (AChEIs, memantine, neuroleptics, benzodiazepines acceptable if stable)
- Age range 50-85
- MMSE > 14 and < 26

Key Exclusion Criteria

- Stroke or TIA within 12 months
- Severe physical disability
- Anticoagulants (ASA or Plavix acceptable)
- *Consider dosage:* changing memory or other medication is a top reason for disqualification, but patients can stay on medication throughout the trial

Questions about E2027?

Contact your Clinical Trial Advocate Today:
Hello@SiteRx.com



**Patient Site
Options**

32

SiteRx is launching E2027 across 14 major states, providing maximal convenience to interested patients